Group 1 - The report indicates that the current market is experiencing a liquidity-driven bull market, with the Shanghai Composite Index having risen approximately 15% in the second half of the year, despite weak macroeconomic fundamentals [1][4] - The report emphasizes the importance of transitioning from a liquidity-driven market to a fundamentals-driven market for sustained growth above the 4000-point level on the Shanghai Composite Index [1][4] - Historical analysis shows that significant year-end rallies typically require low valuations and improved liquidity conditions, with only three instances in the past decade where no rally occurred during this period [2][4] Group 2 - The report highlights that the market is currently in a "high-cut low" phase, where large-cap stocks have outperformed small-cap stocks, and this trend is expected to continue until a new main theme emerges [3][4] - It is noted that the performance of cyclical value stocks is expected to be strong leading into the year-end, particularly in resource and financial sectors, with a historical win rate of 70% for value stocks during this period [3][4] - The report suggests that the technology sector may see a rebound in January, as historical data indicates that growth stocks tend to perform better after the Lunar New Year [3][4] Group 3 - The report discusses the structural rotation in the market, indicating that the technology sector has been focusing on high-certainty trends, particularly in AI hardware, while software applications have lagged [3][4] - It is mentioned that the current high levels of technology stock valuations may lead to increased sensitivity to negative news, suggesting a cautious approach to investing in this sector [3][4] - The report also notes that the performance of the A-share technology sector is closely tied to global trends in AI and the performance of U.S. tech stocks, highlighting the need for careful monitoring of external signals [3][4]

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy in first-line treatment of gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of the III phase clinical study of Nilotinib in first-line treatment of Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharma-B (02595) initiated a registration clinical trial for GFH375 in metastatic pancreatic cancer, marking the first global oral KRAS G12D inhibitor monotherapy controlled chemotherapy III phase study [1] - Xixiangfeng Group (02473) subsidiary signed a business cooperation agreement with Hello Car Rental to develop car rental business in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for GLP-1/GIP receptor dual agonist peptide injection [1] - MIRXES-B (02629) plans to collaborate with Jingtai Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automotive (01728) plans to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) intends to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) announced that seven innovative products, including new indications, were successfully included in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biopharma-B (09887) clinical data for LBL-034 was presented at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Aurantium Extract Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) had five new products successfully included in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) core products were included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported contract sales of approximately 47.7 billion yuan in the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported November equity power generation of 697.23 GWh, a year-on-year increase of 7.77% [2]

Investment Rating - The report maintains an investment rating of "Outperform" with a target price set for the leading stocks [7]. Core Insights - The National Healthcare Security Administration released the "Commercial Health Insurance Innovative Drug Directory (2025)", which includes 19 high-cost innovative drugs, including five CAR-T therapies and two Alzheimer's drugs. This is expected to improve payment difficulties for high-value innovative drugs and provide an additional payment pathway beyond basic medical insurance [3][24]. - The report highlights several promising stocks to watch, including those with high certainty for overseas expansion and those with potential overseas data catalysts [2][22]. Weekly New Drug Market Review - From December 1 to December 7, 2025, the new drug sector saw significant stock movements, with the top five gainers being Beihai Kangcheng (+13.94%), Maibo Pharmaceutical (+11.32%), Jiahe Biotech (+8.38%), Junsheng Tai (+7.14%), and Nuo Si Lan De (+6.27%). Conversely, the top five losers included Shengnuo Pharmaceutical (-15.18%), Shouyao Holdings (-9.06%), Boan Biotech (-8.62%), Tengsheng Bo Pharmaceutical (-8.05%), and Yiming Angke (-7.72%) [1][16]. New Drug Approval and Acceptance Status - This week, one new drug or new indication application was approved, and 16 new drug or new indication applications were accepted in the domestic market [4][28]. Clinical Application Approval and Acceptance Status - A total of 44 new drug clinical applications were approved, and 40 new drug clinical applications were accepted this week [5][31].

Core Viewpoint - The news highlights the passing of Guan Ping, a prominent figure in the Chinese pharmaceutical industry, and acknowledges his significant contributions to the sector and various companies he worked with [2][4]. Group 1: Guan Ping's Contributions - Guan Ping was recognized as a senior professional manager in the Chinese pharmaceutical industry, earning accolades such as the "Top Ten Professional Managers" and "Top Ten Pharmaceutical Elites" [4]. - He played a pivotal role in the marketing of major OTC products like Calcium D and Bai Jia Hei, earning the title "Prince of OTC" for his achievements [4][5]. - His career began in 1988 at Xi'an Janssen, where he became the second local pharmaceutical representative, marking the start of his impactful journey in the industry [4]. Group 2: Career Milestones - A significant turning point in Guan Ping's career occurred in 1997 when he joined Wyeth as a regional marketing director, transitioning the company’s focus from hospital sales to the OTC retail market [4][5]. - Under his leadership, sales of Calcium D increased by nearly 20% in 1998, surpassing hospital sales in the retail market [5]. - In 2001, he joined Dongsheng Technology as a director and vice president, where he successfully revitalized the Bai Jia Hei brand, increasing its sales from over 2 million to more than 200 million [5][6]. Group 3: Innovative Strategies - Guan Ping introduced innovative marketing strategies, such as in-store competitions and training for pharmacy staff, which were unprecedented in the industry at the time [5]. - He recognized the challenges faced by pharmaceutical distributors due to shrinking profit margins and implemented a commission-based model in 2002 to enhance profitability for distributors [6]. - By 2004, the sales of the Dongsheng anti-cold family exceeded 50 million, with Bai Jia Hei achieving a record of 500 million [6].

Core Viewpoint - The approval of SYH2069 injection by the FDA marks a significant milestone for the company, as it is expected to be the first GLP-1/GIP receptor dual agonist to enter clinical trials in China, offering potential for effective weight management and treatment of metabolic diseases [1]. Group 1: Product Development - The SYH2069 injection has received FDA approval to conduct clinical trials in the U.S. [1] - This product selectively activates the cAMP pathway while significantly reducing β-arrestin recruitment, which minimizes receptor internalization and desensitization, thereby enhancing efficacy and duration of effect [1]. - The product is designed to achieve deeper and more sustained weight loss effects due to its long half-life modification technology [1]. Group 2: Clinical Research Findings - In studies involving diet-induced obesity (DIO) mice and non-human primates, SYH2069 demonstrated significantly better weight loss and metabolic improvement compared to existing products on the market [1]. - Toxicology studies in non-human primates indicated good tolerability, with no observed vomiting or gastrointestinal adverse reactions [1]. Group 3: Clinical Application and Value - The approved clinical indication is for weight management in individuals who are obese or overweight with at least one weight-related comorbidity [1]. - The product also shows potential for improving blood glucose control in adult patients with type 2 diabetes mellitus (T2DM), indicating high clinical development value [1].

Core Insights - The company Shiyao Group (01093) has received FDA approval for its GLP-1/GIP receptor dual agonist peptide injection (SYH2069), allowing clinical trials to commence in the United States [1] - This product is expected to be the first GLP-1/GIP dual agonist to enter clinical stages in China, with a mechanism that selectively activates the cAMP pathway while significantly reducing β-arrestin recruitment, leading to improved efficacy and sustained effects [1] - The product demonstrates superior weight loss and metabolic improvement in studies involving diet-induced obesity (DIO) mice and non-human primates compared to existing products [1] - Toxicology studies in non-human primates indicate good tolerability with no observed vomiting or gastrointestinal adverse reactions, suggesting excellent efficacy and safety [1] - The approved clinical indication focuses on weight management for obese or overweight individuals with at least one weight-related comorbidity, and it also shows potential for improving blood glucose control in adults with type 2 diabetes mellitus (T2DM), indicating high clinical development value [1]

Core Viewpoint - The approval of SYH2069 injection by the FDA marks a significant milestone for the company, as it is expected to be the first GLP-1/GIP receptor dual agonist to enter clinical trials in China, potentially offering a new treatment for obesity and metabolic diseases [1] Group 1: Product Development - The product is designed to selectively activate the cAMP pathway while significantly reducing β-arrestin recruitment, which minimizes receptor internalization and desensitization, thereby enhancing efficacy and duration of effect [1] - The long half-life modification technology allows for deeper and more sustained weight loss effects [1] Group 2: Clinical Research Findings - In studies involving diet-induced obesity (DIO) mice and non-human primates, SYH2069 demonstrated significantly better weight loss and metabolic improvement compared to existing products on the market [1] - Toxicology studies in non-human primates indicated good tolerability, with no observed vomiting or gastrointestinal adverse reactions [1] Group 3: Clinical Application and Value - The approved clinical indication is for weight management in individuals who are overweight or obese with at least one weight-related comorbidity [1] - The product also shows potential for improving blood glucose control in adults with type 2 diabetes mellitus (T2DM), indicating high clinical development value [1]

（股份代號：1093） （於香港註冊成立之有限公司） 自願公告 GLP -1 / GIP受體雙偏向性激動多肽注射液（SYH2069注射液） 在美國獲臨床試驗批准 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布，本集團開發的GLP -1 / GIP受體雙偏向性激動多肽注射液（ SYH2069注射液 ）（「該產品」）已 獲得美國食品藥品監督管理局(FDA)批准，可在美國開展臨床試驗。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 – 1 – 本 次 獲 批 的 臨 床 適 應 症 為 肥 胖 或 超 重 合 併 至 少 一 種 體 重 相 關 合 併 症 人 群 的 體 重 管 理 。 此 外，該產品亦具備用於改善成人2型糖尿病(T2DM)患者的血 ...

Core Viewpoint - Yuanhe Pharmaceutical announced the unfortunate passing of its director, Mr. Guan Ping, on December 1, 2025, due to an accident, expressing deep condolences and gratitude for his contributions to the company [1][3]. Group 1: Company Information - Mr. Guan Ping held 500,000 shares of Yuanhe Pharmaceutical, representing 0.81% of the company's total equity [3]. - The company and its employees paid high respect and heartfelt thanks to Mr. Guan for his hard work and outstanding contributions during his tenure [3]. Group 2: Industry Background - Mr. Guan Ping was a seasoned professional in the Chinese pharmaceutical industry, recognized as one of the top ten professional managers and pharmaceutical elites, earning the nickname "Prince of OTC" for his significant contributions to the OTC market [5][6]. - His career included key positions at major pharmaceutical companies such as Xi'an Janssen, Lizhu Group, Wyeth, Shijiazhuang Pharmaceutical Group, and Dongsheng Technology, where he played a pivotal role in launching successful products like Calcium D and Bai Jia Hei [5][6][7]. - Mr. Guan's innovative marketing strategies, such as in-store promotions and training for pharmacy staff, significantly boosted sales, exemplified by the increase in sales of Calcium D by nearly 20% in 1998 [6][7].